Mostrar el registro sencillo del ítem

dc.contributor.authorMurga, Matilde 
dc.contributor.authorFernandez-Capetillo, Oscar 
dc.date.accessioned2024-03-15T11:12:19Z
dc.date.available2024-03-15T11:12:19Z
dc.date.issued2022-11
dc.identifier.citationMol Oncol . 2022 ;16(21):3757-3760.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18965
dc.description.abstractThese are exciting times to be involved in biomedical research. The transition from a scientific hypothesis to a testable therapy is now faster than ever, and new technologies that facilitate drug development are constantly emerging. The rapid development of COVID-19 vaccines provides a clear example of the current pace of drug discovery and its clinical implementation. Importantly, the wide availability of technologies that speed up drug development has also reached oncology, and investigators can now consider several independent strategies when looking to develop a new therapy. This thematic issue provides an overview of recent advances in cancer drug discovery, in areas such as fragment-based drug development, targeting the DNA damage response or the MYC oncogene, senolytic therapies and computational tools that facilitate drug discovery and the selection of treatments in personalized medicine. We are confident that reading these reviews will help those interested in the development of cancer therapies get a broader and updated view of available opportunities and challenges.es_ES
dc.description.sponsorshipResearch in OF laboratory is funded by grants from the Spanish Ministry of Science, Innovation and Universities (PID2021-128722OB-I00, co-financed with European FEDER funds), the Spanish Association Against Cancer (AECC; PROYE20101FERN), Cancerfonden (180640) and the Swedish Research Council (538-2014-31).es_ES
dc.language.isoenges_ES
dc.publisherWiley es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshDrug Discovery es_ES
dc.subject.meshNeoplasms es_ES
dc.subject.meshHumans es_ES
dc.titleEmerging concepts in drug discovery for cancer therapy.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID36321722es_ES
dc.format.volume16es_ES
dc.format.number21es_ES
dc.format.page3757es_ES
dc.identifier.doi10.1002/1878-0261.13325es_ES
dc.contributor.funderEuropean Union (EU)es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderAsociación Española Contra el Cáncer es_ES
dc.contributor.funderSwedish Research Council es_ES
dc.contributor.funderSwedish Cancer Society (Cancerfonden) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1878-0261es_ES
dc.relation.publisherversionhttps://doi.org/10.1002/1878-0261.13325.es_ES
dc.identifier.journalMolecular oncologyes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Inestabilidad Genómicaes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional